Product Name: InsR (1348-1366)
Product Number: PE-01BDI85
Size: | 1 mg | | Price: | 96.00 |
| 5 mg | | $US | 208.00 |
| 20 mg | | | 368.00 |
Peptide Name: InsR (1348-1366)
Product Use: Services as a blocking peptide for use with the InsR-BCT rabbit polyclonal antibody (Cat. No.: AB-NK079-2) that is also available from Kinexus. The peptide sequence is located in the pre-C-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: SLGFKRSYEEHIPYTHMNGC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2368.6 Da
Peptide Purity Percent after Synthesis and Purification: >80
Scientific Background: InsR (IR) is a protein-tyrosine kinase of the TK group and InsR family. It binds and mediates the effects of insulin. Binding of insulin to the receptor results in the downstream phosphorylation of several intracellular signalling components, including insulin receptor substrates (IRS1, 2, 3, 4), Shc, GAB1, CBL, and other intracellular signalling intermediates. Phosphorylated IRS1 recruits and activates the GRB2/SOS complex, which in turn leads to the activation of the Ras/Raf/MAP2K/MAPK signalling pathway. This pathway is mainly involved in the regulation of cell growth, survival, and cellular differentiation resulting from insulin signalling. Insulin binds to InsR to trigger autophosphorylation at many sites, including Y999, S1001, Y1185, Y1189, Y1190, S1332, S1333, Y1355, Y1361 and T1375, which increases its phosphotransferase activity. Protein interactions are induced with phosphorylation of Y999 (with SOCS3) and Y1185, Y1189 and Y1190 (with IRS2 and PTP1B). Phosphorylation of Y992 and Y1011 inhibits the phosphotransferase activity of InsR. Binding of insulin to the InsR stimulates glucose uptake. Insulin receptor signalling helps to maintain fuel homeostasis and prevent diabetes. InsR signalling also increases the regeneration of adult beta-cells and the central control of nutrient homeostasis. InsR has also been linked with the development of insulin resistance, familial hyperinsulinemic hypoglycemia Type 5 (HHF5), and gastric adenocarcinomas. InsR appears to be an oncoprotein (OP). Over activation of the insulin receptor signalling pathway has been linked to the development of several cancer types, including breast cancer. In addition, elevated InsR expression in breast cancer is correlated with poor patient survival.